Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2004 3
2006 4
2007 5
2011 4
2012 4
2013 4
2014 2
2015 2
2018 3
2019 1
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Blum KA, Bartlett NL. Blum KA, et al. Expert Opin Biol Ther. 2004 Aug;4(8):1323-31. doi: 10.1517/14712598.4.8.1323. Expert Opin Biol Ther. 2004. PMID: 15268665 Review.
Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for t …
Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB, Bondly C, Micallef IN. Johnston PB, et al. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9. doi: 10.1586/14737140.6.6.861. Expert Rev Anticancer Ther. 2006. PMID: 16761929 Review.
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelat …
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hod …
Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).
Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Mukherjee S, et al. Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. doi: 10.1016/j.hemonc.2017.12.004. Epub 2018 Feb 1. Hematol Oncol Stem Cell Ther. 2018. PMID: 29406240 Free article. Review.
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. ...There is a concern for development of hypersensitivity reactions with Ibritumomab, especially in patien
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. Morschhauser F, et al. J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547079 Clinical Trial.
PURPOSE: Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. ...For (90)Y-ibritumomab conso …
PURPOSE: Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90 …
Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Vanazzi A, Grana C, Crosta C, Pruneri G, Rizzo S, Radice D, Pinto A, Calabrese L, Paganelli G, Martinelli G. Vanazzi A, et al. Hematol Oncol. 2014 Mar;32(1):10-5. doi: 10.1002/hon.2078. Epub 2013 May 20. Hematol Oncol. 2014. PMID: 23696416 Clinical Trial.
We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma--arisen at any extranodal site--rec …
We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone l …
Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
Krasner C, Joyce RM. Krasner C, et al. Curr Pharm Biotechnol. 2001 Dec;2(4):341-9. doi: 10.2174/1389201013378545. Curr Pharm Biotechnol. 2001. PMID: 11762415 Review.
Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes. ...
Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) th …
Yttrium 90 Ibritumomab Tiuxetan.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999770 Free Books & Documents. Review.
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. ...
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is avai …
Consolidation with (90) Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Miura K, Tsujimura H, Masaki Y, Iino M, Takizawa J, Maeda Y, Yamamoto K, Tamura S, Yoshida A, Yagi H, Yoshida I, Kitazume K, Masunari T, Choi I, Kakinoki Y, Suzuki R, Yoshino T, Nakamura S, Hatta Y, Yoshida T, Kanno M. Miura K, et al. Hematol Oncol. 2021 Feb;39(1):51-59. doi: 10.1002/hon.2809. Epub 2020 Oct 7. Hematol Oncol. 2021. PMID: 32978820 Clinical Trial.
This study evaluated the efficacy and safety of consolidation with (90) Yttrium-ibritumomab tiuxetan ((90) Y-IT) after re-induction therapy with BR in patients with previously treated FL. ...
This study evaluated the efficacy and safety of consolidation with (90) Yttrium-ibritumomab tiuxetan ((90) Y-IT) after re-indu …
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS; Children's Oncology Group. Cooney-Qualter E, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s. doi: 10.1158/1078-0432.CCR-07-1060. Clin Cancer Res. 2007. PMID: 17875803 Free article. Clinical Trial.
PURPOSE: The prognosis for children with recurrent CD20+ non-Hodgkin's lymphoma is dismal. A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non …
PURPOSE: The prognosis for children with recurrent CD20+ non-Hodgkin's lymphoma is dismal. A radiolabeled anti-CD20 antibody, 90yttrium
34 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page